Tag: MONOGRAPH

  • CDD-0102

    Selective M1 muscarinic acetylcholine receptor partial agonist of the tetrahydropyrimidine-oxadiazole structural class

    A functionally selective partial agonist at the M1 muscarinic acetylcholine receptor developed at the University of Toledo as a cognitive enhancer and neuroprotective agent for Alzheimer’s disease, distinguished from earlier muscarinic agonists by subtype selectivity, low cholinergic adverse-event burden, and oral bioavailability.

    Abstract

    CDD-0102, the hydrochloride salt of 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine (designated CDD-0102A in its salt form), is a functionally selective partial agonist at the M1 subtype of the muscarinic acetylcholine receptor developed at the University of Toledo College of Pharmacy under the direction of W.S. Messer Jr. as a candidate therapeutic for Alzheimer’s disease and related cognitive disorders. The compound occupies the orthosteric acetylcholine-binding site of the M1 receptor with partial agonist intrinsic activity sufficient to activate phospholipase C-coupled signaling, stimulate non-amyloidogenic processing of amyloid precursor protein (APP) through alpha-secretase, and enhance cognitive function in rodent models of cholinergic deficit, while exhibiting minimal functional activity at M2, M4, and M5 muscarinic subtypes and only weak activity at M3 receptors. This functional selectivity profile distinguishes CDD-0102 from the first-generation M1-preferring muscarinic agonists (xanomeline, sabcomeline, talsaclidine, cevimeline) that produced dose-limiting cholinergic adverse events (salivation, gastrointestinal disturbance, diaphoresis) attributable to activation of peripheral M2 and M3 receptors, a limitation that terminated or constrained the clinical development of each of those compounds in the Alzheimer’s indication. The pharmacological characterization of CDD-0102 encompasses M1-selective receptor binding, stimulation of soluble APP-alpha (sAPPalpha) secretion from Chinese hamster ovary cells stably expressing human M1 receptors, neuroprotective activity in cell culture, brain penetration following systemic administration in rodents, oral bioavailability, and a favorable acute toxicity profile. More recent preclinical work has extended the pharmacological profile to autism spectrum disorder models, demonstrating that CDD-0102A attenuates stereotyped motor behaviors (self-grooming, digging) and modulates glutamate efflux in dorsolateral striatum of the BTBR T+ Itpr3tf/J mouse, a model of autism-relevant repetitive behavior and social deficit. The compound advanced through preclinical development with support from the National Center for Advancing Translational Sciences (NCATS) Bridging Interventional Development Gaps (BrIDGs) program, which funded the IND-enabling studies including synthetic scale-up, formulation, pharmacokinetics, and toxicology. An Investigational New Drug (IND) application was filed with the United States Food and Drug Administration, and Phase 1 clinical testing was initiated. Published results from Phase 1 clinical evaluation have not appeared in the peer-reviewed literature as of the most recent monograph revision. The compound is not registered as a marketed medicine in any jurisdiction. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Xanomeline-Trospium

    Fixed-dose combination of an M1/M4-preferring muscarinic acetylcholine receptor agonist and a peripherally restricted non-selective muscarinic antagonist

    A first-in-class muscarinic agonist combination pairing the centrally acting M1/M4-preferring agonist xanomeline with the peripherally restricted muscarinic antagonist trospium chloride, approved by the United States Food and Drug Administration in September 2024 for the treatment of schizophrenia in adults, representing the first non-dopamine-D2-blocking antipsychotic mechanism registered for psychotic illness.

    Abstract

    Xanomeline-trospium (KarXT; marketed as Cobenfy) is a fixed-dose oral combination of xanomeline tartrate, a functionally selective muscarinic acetylcholine receptor agonist with preferential activity at the M1 and M4 receptor subtypes, and trospium chloride, a quaternary ammonium muscarinic antagonist that does not appreciably cross the blood-brain barrier. The combination was designed to preserve the central antipsychotic and procognitive effects of muscarinic M1/M4 agonism while mitigating the dose-limiting peripheral cholinergic adverse events (nausea, vomiting, diarrhea, hypersalivation, diaphoresis) that had previously terminated the clinical development of xanomeline as a monotherapy agent. The United States Food and Drug Administration approved xanomeline-trospium on 26 September 2024 for the treatment of schizophrenia in adults, making it the first antipsychotic mechanism approved since the introduction of the dopamine D2 receptor antagonist and partial agonist classes and the first muscarinic-based treatment registered for any psychotic disorder.

    Xanomeline was originally synthesized in a collaboration between Eli Lilly and Novo Nordisk in the early 1990s under the development code LY-246708. Initial clinical development targeted Alzheimer’s disease, where a 343-patient Phase 2 trial (Bodick et al. 1997) demonstrated stabilization of cognitive decline and significant dose-dependent reductions in behavioral and psychological symptoms including hallucinations, delusions, agitation, and vocal outbursts. However, peripheral cholinergic adverse events led to unacceptable dropout rates and the Alzheimer’s program was discontinued. A subsequent proof-of-concept trial in schizophrenia (Shekhar et al. 2008) confirmed antipsychotic-like activity through a non-dopaminergic mechanism but was similarly limited by tolerability. The critical innovation was the combination with trospium chloride, a muscarinic antagonist previously approved for overactive bladder (Sanctura, Allergan) that is restricted to the peripheral compartment by its quaternary ammonium structure and does not undergo cytochrome P450 metabolism. This combination strategy was advanced by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb for approximately 14 billion United States dollars in 2024.

    The registration of xanomeline-trospium was supported by three randomized, double-blind, placebo-controlled, 5-week Phase 3 trials (EMERGENT-1, EMERGENT-2, EMERGENT-3) in adults with schizophrenia experiencing acute psychosis. In pooled analyses across all three trials, xanomeline-trospium produced a statistically significant reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (least squares mean difference, minus 9.9 points; 95 percent confidence interval, minus 12.4 to minus 7.3; p less than 0.0001; Cohen’s d effect size, 0.65). Effects were observed across positive symptom, negative symptom, and general psychopathology PANSS subscales and on the Clinical Global Impression-Severity scale. Long-term safety and efficacy were characterized in the 52-week open-label extension trials EMERGENT-4 and EMERGENT-5, which demonstrated sustained symptom improvement, a mean change in body weight of minus 1.9 kilograms from acute trial baseline, no clinically meaningful changes in prolactin levels, and no treatment-emergent akathisia or tardive dyskinesia. The most common adverse events were gastrointestinal (nausea, dyspepsia, constipation, vomiting) and were generally mild to moderate, transient, and manageable without treatment discontinuation in most patients.

    The compound is currently in Phase 3 development for additional indications including psychosis associated with Alzheimer’s disease (ADEPT program), agitation associated with Alzheimer’s disease (ADAGIO program), and cognitive impairment in Alzheimer’s disease. An enteric-coated xanomeline formulation (KarX-EC) is in development with the aim of further reducing gastrointestinal adverse events. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • MitoQ

    Mitochondria-targeted ubiquinone-derived antioxidant conjugated to a triphenylphosphonium cation

    A synthetic coenzyme Q10 analog covalently linked to a lipophilic triphenylphosphonium moiety that drives selective mitochondrial accumulation, enabling targeted quenching of reactive oxygen species at the inner mitochondrial membrane with demonstrated vascular, hepatoprotective, and anti-inflammatory activity in human clinical studies.

    Abstract

    Mitoquinone mesylate (MitoQ) is a mitochondria-targeted antioxidant composed of a ubiquinone moiety covalently linked via a ten-carbon alkyl chain to a triphenylphosphonium (TPP+) cation, enabling rapid permeation of lipid bilayers and accumulation within the mitochondrial matrix at concentrations up to several hundred-fold above extracellular levels, driven by the large negative mitochondrial membrane potential (approximately negative 150 to negative 180 millivolts). The compound was developed in the 1990s by Robin Smith and Michael Murphy at the University of Otago, New Zealand, as an approach to overcoming the failure of conventional untargeted antioxidants (including native coenzyme Q10) to achieve therapeutically meaningful concentrations within mitochondria, the principal intracellular source of reactive oxygen species (ROS). Within the mitochondrion, MitoQ adsorbs to the matrix-facing leaflet of the inner mitochondrial membrane, where the ubiquinone head group is reduced to the active antioxidant ubiquinol form by complex II (succinate:ubiquinone oxidoreductase) of the electron transport chain. The ubiquinol form scavenges superoxide, hydroxyl radicals, and peroxyl radicals, preventing lipid peroxidation of cardiolipin and other mitochondrial membrane phospholipids. Following oxidation during radical quenching, the resulting ubiquinone is re-reduced by complex II, establishing a catalytic antioxidant cycle that permits repeated radical neutralization from a single molecule. This recycling mechanism distinguishes MitoQ from stoichiometric antioxidants such as alpha-tocopherol that are consumed in the quenching reaction. Preclinical pharmacology has demonstrated protective effects in rodent models of ischemia-reperfusion injury, diabetic nephropathy, nonalcoholic fatty liver disease, sepsis-associated organ failure, pulmonary hypertension, Alzheimer’s disease, doxorubicin-induced cardiomyopathy, cisplatin nephrotoxicity, and metabolic syndrome, with consistent reductions in mitochondrial oxidative damage markers, preservation of mitochondrial membrane potential, and attenuation of downstream inflammatory signaling through suppression of NF-kappaB activation and NLRP3 inflammasome assembly. Four completed human clinical trials define the current clinical evidence base. A 2024 exploratory pilot trial (Jain et al. 2024) of MitoQ as post-exposure prophylaxis against SARS-CoV-2 infection reported reduced infection rates and symptom duration in the treatment group versus matched controls. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • CP2

    Tricyclic pyrone mild mitochondrial complex I inhibitor with direct amyloid-beta binding activity

    A cell-permeable tricyclic pyranopyrone synthesized at Kansas State University as an anti-amyloidogenic agent, subsequently characterized as a mild inhibitor of mitochondrial complex I that activates AMPK-dependent neuroprotective signaling, crosses the blood-brain barrier, and reduces amyloid-beta, phosphorylated tau, oxidative stress, and neuroinflammation in multiple transgenic mouse models of familial Alzheimer’s disease.

    Abstract

    CP2 is a synthetic tricyclic pyrone (pyranopyrone) small molecule originally developed as part of a structure-activity exploration of anti-amyloidogenic agents in the laboratory of Duy H. Hua at Kansas State University and first reported in the biomedical literature as a cell-permeable inhibitor of amyloid-beta oligomeric complex formation in the MC65 neuroblastoma conditional expression system by Maezawa et al. (2006) [1]. The compound consists of a fused tricyclic pyranopyrone skeleton bearing an adenine moiety attached through its N3′ nitrogen to the C7 isopropyl substituent of the cyclohexane ring. CP2 exists as two diastereomers, designated D1 and D2, with distinct pharmacological activity and toxicity profiles that have been resolved by X-ray crystallography and cryo-electron microscopy at 3.25 to 3.27 angstrom resolution [2]. The D1 diastereomer is the more pharmacologically active form. The compound was initially characterized as a direct binder of amyloid-beta peptides, with exceptionally high binding affinity to amyloid-beta 40 (Kd approximately 5.05 nanomolar) and high affinity to amyloid-beta 42 (Kd approximately 269 nanomolar), and as an inhibitor of amyloid-beta oligomerization and fibril formation in surface plasmon resonance and atomic force microscopy assays [3, 4]. Subsequent mechanistic investigation by Zhang et al. (2015) identified the primary intracellular target as mitochondrial complex I (NADH:ubiquinone oxidoreductase), the first and largest enzyme complex of the electron transport chain [5]. Molecular dynamics simulations and cryo-electron microscopy demonstrated that the cationic CP2 molecule competes with flavin mononucleotide for binding to the redox subunit of human mitochondrial complex I, leading to mild (partial) inhibition of complex I activity, elevated AMP-to-ATP ratio, and consequent activation of AMP-activated protein kinase (AMPK) in neurons and in mouse brain without inducing oxidative damage or inflammation [5, 6]. In vivo, CP2 is orally bioavailable, penetrates the blood-brain barrier, and accumulates in neuronal mitochondria. The compound also prevents aggregation and reverses cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons, extending the potential disease relevance beyond Alzheimer’s disease to Huntington’s disease [10]. A 2025 study by Gao et al. demonstrated that mitochondrial complex I deficiency alone induces Alzheimer’s disease-like transcriptomic signatures in the brain, and that these signatures are partially reversible by CP2 treatment, providing further mechanistic support for the therapeutic strategy [11]. CP2 has not entered human clinical trials. The compound remains a preclinical research tool and investigational candidate. Structure-activity relationship studies have produced a next-generation analog, C458 (cis-(N-(pyridin-4-ylmethyl)-2-(3-(m-tolyloxy)cyclohexyl)propan-1-amine)), with improved drug-like properties, favorable pharmacokinetics, minimal off-target effects, and excellent brain penetrance [2, 12]. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Fluvoxamine

    Selective serotonin reuptake inhibitor with high-affinity sigma-1 receptor agonism

    A 2-aminoethyl oxime ether SSRI developed at Kali-Duphar as an antidepressant and anti-obsessional agent, distinguished from other serotonin reuptake inhibitors by potent sigma-1 receptor agonism and downstream anti-inflammatory, cytoprotective, and endoplasmic reticulum chaperone activity.

    Abstract

    Fluvoxamine, the (E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime, is a selective serotonin reuptake inhibitor (SSRI) of the 2-aminoethyl oxime ether structural class, first introduced in Switzerland in 1983 as Floxyfral and approved by the United States Food and Drug Administration in December 1994 for the treatment of obsessive-compulsive disorder (OCD). It is marketed in approximately 80 countries under the trade names Luvox, Fevarin, Faverin, Floxyfral, and Dumyrox for indications including OCD, social anxiety disorder (SAD), and major depressive disorder (MDD), with the extended-release formulation (Luvox CR) approved in the United States in 2008 for both OCD and SAD. Fluvoxamine is pharmacologically distinguished from the other marketed SSRIs (fluoxetine, sertraline, paroxetine, citalopram, escitalopram) by its potent agonism at the sigma-1 receptor, a ligand-regulated endoplasmic reticulum chaperone protein, with a binding affinity (Ki approximately 36 nM) that is the highest of any clinically used SSRI and approximately 10-fold greater than that of sertraline, the next most potent sigma-1 ligand in the class [1, 2]. The sigma-1 receptor activity, formally characterized by Narita et al. (1996) and subsequently extended by multiple laboratory groups in rodent models and by Hashimoto and colleagues in translational studies, drives a pharmacological profile that extends substantially beyond serotonin reuptake inhibition: activation of the sigma-1 receptor chaperone at the mitochondria-associated endoplasmic reticulum membrane (MAM) modulates the inositol 1,4,5-trisphosphate receptor (IP3R), stabilizes the IRE1-BiP complex under endoplasmic reticulum stress, suppresses NLRP3 inflammasome and NF-kappaB-driven proinflammatory cytokine release, and potentiates nerve growth factor-induced neurite outgrowth in neuronal cell models [3, 4, 5]. Pharmacokinetics in humans are characterized by near-complete gastrointestinal absorption, approximately 53 percent oral bioavailability due to first-pass hepatic metabolism, a plasma elimination half-life of 12 to 15 hours after single doses (extended at steady state owing to nonlinear pharmacokinetics from autoinhibition of CYP1A2 and CYP2C19), and oxidative demethylation through CYP2D6 and CYP1A2 followed by glucuronide conjugation and renal excretion [7, 8]. Fluvoxamine is itself a potent inhibitor of CYP1A2 and CYP2C19 and a moderate inhibitor of CYP3A4 and CYP2C9, producing clinically significant drug-drug interactions with theophylline, tizanidine, alosetron, clozapine, warfarin, and ramelteon, among others [9]. The compound is well tolerated at registered doses; the principal adverse events are nausea (up to 40 percent), somnolence, insomnia, headache, and asthenia, with serotonin syndrome as a rare but serious risk in combination with other serotonergic agents or monoamine oxidase inhibitors. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Dihydro-NMN

    Reduced pyridine nucleotide and potent NAD+ precursor of the dihydronicotinamide mononucleotide class

    A reduced-form nicotinamide mononucleotide that bypasses canonical salvage pathway enzymes to elevate cellular NAD+ and NADH more rapidly and to a greater extent than its oxidized counterpart NMN, with emerging preclinical evidence in renal cytoprotection, metabolic reprogramming, and anti-proliferative activity.

    Abstract

    Dihydronicotinamide mononucleotide (NMNH), also designated reduced nicotinamide mononucleotide or dihydro-NMN, is the 1,4-dihydropyridine analog of beta-nicotinamide mononucleotide (NMN). The compound differs from NMN by a single additional hydrogen at the C-4 position of the nicotinamide ring, converting the aromatic pyridinium to a non-aromatic 1,4-dihydropyridine and conferring distinct biochemical, pharmacokinetic, and pharmacological properties. NMNH was first characterized as a potent nicotinamide adenine dinucleotide (NAD+) precursor in mammalian systems in two independent 2021 reports: Zapata-Perez et al. in The FASEB Journal demonstrated that NMNH increases NAD+ levels to a substantially greater extent and faster than NMN or nicotinamide riboside (NR) across multiple tissues in mice, while Liu et al. in the Journal of Proteome Research showed that NMNH potently enhances NAD+ and NADH, suppresses glycolysis and the tricarboxylic acid cycle, induces reductive stress, and inhibits cell growth in hepatocellular carcinoma cells. The metabolic pathway of NMNH is mechanistically distinct from that of NMN: NMNH is converted directly to NADH by nicotinamide mononucleotide adenylyltransferase (NMNAT) without requiring nicotinamide phosphoribosyltransferase (NAMPT) or nicotinamide riboside kinase (NRK), the two rate-limiting enzymes of the canonical salvage and Preiss-Handler pathways. The resulting NADH is then oxidized to NAD+ by cellular oxidoreductases, producing a net elevation of both reduced and oxidized pyridine dinucleotide pools. In vivo, intraperitoneal administration of NMNH to mice elevates hepatic NAD+ approximately five-fold and renal NAD+ approximately two-fold, with significant increases also observed in brain, skeletal muscle, brown adipose tissue, and heart, tissues in which equivalent doses of NMN produce no statistically significant NAD+ elevation. The Zapata-Perez et al. study additionally demonstrated that NMNH protects conditionally immortalized proximal tubular epithelial cells against hypoxia and reoxygenation injury, reducing expression of the kidney injury biomarker Kim-1 and the mitochondrial dysfunction marker Tfam, establishing a preclinical basis for renal cytoprotection. The Liu et al. metabolomic analysis revealed that NMNH-treated cells exhibit marked suppression of glycolytic intermediates (glucose-6-phosphate, fructose-1,6-bisphosphate, phosphoenolpyruvate, pyruvate) and tricarboxylic acid cycle intermediates (citrate, alpha-ketoglutarate, succinate, fumarate, malate), accompanied by cell cycle arrest and growth inhibition. The compound induces cellular reductive stress through elevation of the NADH/NAD+ ratio, which paradoxically increases reactive oxygen species (ROS) production, linking the reductive stress phenotype to the anti-proliferative activity. NMNH is prepared by chemical reduction of NMN with thiourea dioxide in alkaline aqueous solution or by enzymatic cleavage of NADH with NADH pyrophosphatase (NudC). The compound is supplied as the disodium salt (CAS 108347-85-9) and is commercially available from multiple research chemical suppliers. No regulatory approval exists for NMNH in any jurisdiction; the compound is sold as a dietary supplement or research reagent. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • SRT2104

    Selective small-molecule allosteric activator of NAD-dependent protein deacetylase sirtuin 1 (SIRT1)

    A second-generation imidazothiazole-scaffold sirtuin 1 activator developed by Sirtris Pharmaceuticals and advanced through multiple Phase 2 clinical programs by GlaxoSmithKline, distinguished from first-generation sirtuin-activating compounds by high target selectivity and favorable oral pharmacokinetics.

    Abstract

    SRT2104 (GSK2245840) is a synthetic, orally bioavailable, small-molecule allosteric activator of the NAD-dependent protein deacetylase sirtuin 1 (SIRT1, silent mating type information regulation 2 homolog 1), developed at Sirtris Pharmaceuticals and subsequently advanced into clinical trials by GlaxoSmithKline following the 2008 acquisition of Sirtris for approximately 720 million United States dollars. The compound is a second-generation sirtuin-activating compound (STAC) built on an optimized imidazo[2,1-b]thiazole scaffold and is reported to activate SIRT1 deacetylase activity approximately 1000-fold more potently than the natural polyphenol resveratrol in fluorophore-tagged peptide substrate assays, with minimal activity against a panel of more than 180 non-SIRT1 targets including kinases, G-protein-coupled receptors, nuclear receptors, ion channels, enzymes, and transporters [1, 2]. The allosteric mechanism involves binding to the N-terminal domain of SIRT1, lowering the Michaelis constant (Km) for the acetylated protein substrate without competing with either the NAD cofactor or the substrate acetyl-lysine site [3]. Downstream consequences of SIRT1 activation by SRT2104 include deacetylation and functional modulation of the transcription factor p53, the RelA/p65 subunit of nuclear factor kappa B (NF-kB), forkhead box protein O3 (FOXO3), peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), and signal transducer and activator of transcription 3 (STAT3), producing composite anti-inflammatory, metabolic, and cytoprotective effects that have been characterized across a broad range of preclinical disease models [4, 5].

    The variable and non-dose-proportional pharmacokinetic profile has been identified as a principal limitation of the compound for clinical development in its current oral formulation. SRT2104 is poorly soluble in water and is formulated as a lipid-based oral capsule to improve bioavailability.

    Clinical evaluation has spanned at least seven registered clinical trials across multiple indications. A separate cardiometabolic study in type 2 diabetic subjects reported trends toward improved endothelial function and arterial stiffness [9]. In a human endotoxemia model, SRT2104 pretreatment significantly reduced lipopolysaccharide-induced cytokine release (interleukin-6, interleukin-8) and coagulation activation, representing the first human demonstration of anti-inflammatory and anticoagulant activity consistent with pharmacological SIRT1 activation [12].

    Preclinical pharmacology is extensive. The Mercken et al. (2014) study at the National Institute on Aging demonstrated that SRT2104 extends both mean and maximum lifespan of male mice fed a standard diet by 9.7 percent and 4.9 percent respectively, with preserved bone mineral density, muscle mass, motor coordination, and insulin sensitivity [13]. The Jiang et al. (2014) study demonstrated blood-brain barrier penetration, attenuation of brain atrophy, improvement of motor function, and extension of median lifespan by approximately 16 percent in N171-82Q Huntington disease model mice [14]. Additional preclinical evidence spans emphysema, sepsis, neonatal white matter injury, microglia polarization, dendritic outgrowth, and auditory cell senescence. GlaxoSmithKline discontinued active clinical development of SRT2104 following the 2013 closure of the Sirtris unit, though the compound remains widely used as a reference SIRT1 activator in academic and preclinical research. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • EPI-743

    Para-benzoquinone 15-lipoxygenase inhibitor and redox-active cytoprotectant derived from alpha-tocotrienol quinone

    A synthetic vitamin E-derived para-benzoquinone developed by Edison Pharmaceuticals as a potent inhibitor of 15-lipoxygenase and augmenter of intracellular glutathione biosynthesis, advanced through clinical evaluation in Leigh syndrome, Leber hereditary optic neuropathy, Friedreich ataxia, and other inherited mitochondrial respiratory chain diseases.

    Abstract

    EPI-743, now designated vatiquinone (INN) and previously referred to by the development codes PTC-743 and alpha-tocotrienol quinone, is a synthetic para-benzoquinone derived from the chromanone ring system of vitamin E (alpha-tocotrienol) that was identified in a phenotypic screen for small molecules capable of preventing oxidative cell death induced by L-buthionine-(S,R)-sulfoximine (BSO), an irreversible inhibitor of gamma-glutamylcysteine synthetase and therefore of de novo glutathione biosynthesis. The compound is approximately 1,000- to 10,000-fold more potent than coenzyme Q10 or idebenone in protecting mitochondrial disease and Friedreich ataxia patient fibroblasts in oxidative stress assays, a potency differential attributed to its capacity to serve as a substrate for NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase) and thereby to replenish reduced intracellular glutathione and stabilize cellular redox balance. The mechanistic target has subsequently been identified as 15-lipoxygenase (15-LO), an oxidoreductase enzyme that catalyzes the peroxidation of polyunsaturated fatty acids under conditions of glutathione depletion or glutathione peroxidase 4 (GPX4) inactivation, a process now recognized as the lipid peroxidation arm of ferroptotic cell death. Vatiquinone is therefore classified as a first-in-class selective inhibitor of 15-lipoxygenase with secondary redox-modulatory activity through NQO1-dependent glutathione replenishment. The compound was discovered at Edison Pharmaceuticals (Mountain View, California), a company founded by Guy Miller and subsequently renamed BioElectron Technology Corporation in 2017. PTC Therapeutics acquired substantially all of BioElectron’s assets, including the vatiquinone program, in October 2019 for approximately $210 million. The clinical development program has spanned multiple inherited mitochondrial diseases and related conditions characterized by oxidative stress, mitochondrial dysfunction, and ferroptotic cell death. Open-label and emergency-protocol studies conducted between 2011 and 2017 evaluated EPI-743 in Leigh syndrome (Martinelli et al. 2012, ten pediatric patients, statistically significant reversal of disease progression on the Newcastle Pediatric Mitochondrial Disease Scale), in Leber hereditary optic neuropathy (Sadun et al. 2012, five patients, arrest of disease progression and reversal of visual loss in four of five subjects), in a heterogeneous cohort of genetically confirmed mitochondrial respiratory chain diseases (Enns et al. 2012, fourteen patients, clinical improvement in eleven of twelve survivors), and in Pearson syndrome. A Phase 2 study in Friedreich ataxia demonstrated safety and tolerability over two years. The pivotal registration-directed program is the Phase 3 MOVE-FA trial, a randomized, placebo-controlled, 72-week study in 146 pediatric and adult patients with Friedreich ataxia. The trial did not meet its primary endpoint of statistically significant change from baseline in the modified Friedreich Ataxia Rating Scale (mFARS) in the primary analysis population (p = 0.14), though statistically significant effects were observed on the pre-specified upright stability subscale (p = 0.021) and in the per-protocol population (p < 0.05). Long-term extension data demonstrated a 3.7-point benefit on mFARS relative to a matched natural history cohort from the FACOMS disease registry at 144 weeks, representing a 50 percent slowing of disease progression over three years. PTC Therapeutics submitted a New Drug Application to the United States Food and Drug Administration, which granted Priority Review with a PDUFA target action date of August 19, 2025. The FDA subsequently issued a Complete Response Letter, indicating that additional efficacy data would be required to support approval. The compound is administered three times daily with food to enhance bioavailability. The safety profile across more than 500 patients and treatment durations of up to 10 years is favorable, with no treatment-related serious adverse events reported in key long-term studies. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • 17-alpha-Estradiol

    Non-feminizing endogenous estradiol stereoisomer with 5-alpha-reductase inhibitory activity and lifespan-extending properties

    A naturally occurring 17-alpha-epimer of estradiol with approximately 100-fold reduced classical estrogen receptor affinity, topical registration as alfatradiol for androgenetic alopecia, and reproducible male-specific lifespan extension in the NIA Interventions Testing Program, mediated through estrogen receptor alpha signaling in the hypothalamus and liver.

    Abstract

    17-alpha-Estradiol (estra-1,3,5(10)-triene-3,17-alpha-diol; CAS 57-91-0; alfatradiol; molecular formula C18H24O2; molecular weight 272.39 g/mol) is the 17-alpha-stereoisomer of the principal mammalian estrogen 17-beta-estradiol, distinguished solely by the axial (alpha) orientation of the hydroxyl group at carbon 17 of the steroid D-ring. The compound occurs endogenously at low concentrations in mammalian brain and peripheral tissues and has been characterized since the 1950s as a weak estrogen with approximately 100-fold lower binding affinity for the classical nuclear estrogen receptors ER-alpha and ER-beta relative to the 17-beta-epimer [1, 2]. Despite this reduced receptor engagement, 17-alpha-estradiol retains potent estrogen receptor-independent antioxidant activity equivalent to 17-beta-estradiol in lipid peroxidation assays and neuroprotection models [3, 4], inhibits 5-alpha-reductase and aromatase in skin and hair follicle tissue (the basis for its topical registration as alfatradiol in several European jurisdictions for androgenetic alopecia) [5, 6], and has emerged as one of the most robustly validated lifespan-extending compounds in the National Institute on Aging Interventions Testing Program (ITP), a rigorous, multi-site, genetically heterogeneous mouse longevity screening platform.

    The ITP demonstrated that dietary 17-alpha-estradiol at 14.4 parts per million (approximately 2 mg/kg/day mouse-equivalent) extended median lifespan by approximately 19 percent in male UM-HET3 mice when initiated at 16 months of age and by approximately 11 percent when initiated at 20 months, with no lifespan extension observed in female mice at any initiation age [7, 8, 9]. The male specificity of the lifespan effect has been replicated across three independent ITP sites (the Jackson Laboratory, the University of Michigan, and the University of Texas Health Science Center) and is among the largest and most reproducible lifespan extensions reported in the ITP, comparable in magnitude to acarbose and exceeded only by rapamycin. The sex-specific pattern has driven substantial mechanistic investigation. Stout et al. (2017) demonstrated that 17-alpha-estradiol alleviates age-related metabolic and inflammatory dysfunction in male mice without inducing feminization, with treated males showing reduced fasting glucose, reduced fasting insulin, reduced glycosylated hemoglobin, reduced visceral adiposity, reduced circulating and adipose tissue pro-inflammatory cytokines, and increased AMP-activated protein kinase activity in visceral adipose tissue [10]. Steyn et al. (2018) established that 17-alpha-estradiol acts through hypothalamic pro-opiomelanocortin (POMC) expressing neurons to reduce feeding behavior, with near-complete loss of the anorectic response in POMC-neuron-ablated mice [11]. Mann et al. (2020) demonstrated through liver-specific and global ER-alpha knockout models that the metabolic health benefits of 17-alpha-estradiol (reductions in fasting insulin, HbA1c, glucose intolerance, and visceral adiposity) are mediated through estrogen receptor alpha, resolving prior uncertainty about whether a non-classical receptor was responsible [12]. Garratt et al. (2017, 2018) reported that males, but not females, metabolize 17-alpha-estradiol into one or more estriol derivatives, and that the sex-specific beneficial effects may depend on a downstream metabolite rather than on the parent compound [13, 14].

    The compound has limited human clinical data. Topical formulations (alfatradiol 0.025 percent solution, marketed as Ell-Cranell alpha) are registered in Germany, Austria, and several other European jurisdictions for androgenetic alopecia in men and women, with demonstrated stabilization of hair loss through local 5-alpha-reductase inhibition and aromatase induction [5, 6]. No clinical trials of oral 17-alpha-estradiol for longevity, metabolic, or neuroprotective endpoints have been completed or registered in humans as of the monograph revision date.

    This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Honokiol

    Biphenyl neolignan polyphenol with pleiotropic GABAA receptor positive allosteric modulation, SIRT3 activation, and multi-pathway anti-inflammatory and antineoplastic activity

    A naturally occurring biphenolic neolignan isolated from Magnolia officinalis bark, distinguished by positive allosteric modulation of GABAA receptors, direct activation of mitochondrial sirtuin-3, and broad-spectrum preclinical activity across oncology, neuroprotection, anxiolysis, and inflammation.

    Abstract

    Honokiol (3′,5-di-2-propenyl-1,1′-biphenyl-2,4′-diol) is a biphenyl neolignan polyphenol isolated principally from the bark, seed cones, and leaves of Magnolia officinalis and related species of the genus Magnolia, a botanical source with documented use in traditional Chinese, Japanese, and Korean medicine for over two thousand years. The compound has attracted substantial modern pharmacological interest owing to a pleiotropic mechanism profile that includes positive allosteric modulation of both synaptic and extrasynaptic GABAA receptors at a site distinct from the benzodiazepine binding site; direct activation of the mitochondrial deacetylase sirtuin-3 (SIRT3) with consequent enhancement of mitochondrial respiration, ATP production, and antioxidant defense; agonism at peroxisome proliferator-activated receptor gamma (PPARgamma); inhibition of nuclear factor kappa-B (NF-kB) and signal transducer and activator of transcription 3 (STAT3) signaling; modulation of the PI3K/Akt/mTOR axis; and disruption of the PSD95-nNOS protein-protein interaction at glutamatergic synapses. The preclinical pharmacology of honokiol spans four principal domains. In oncology, honokiol inhibits proliferation, induces apoptosis through both intrinsic and extrinsic pathways, suppresses angiogenesis, and reduces metastatic potential in cell-line and xenograft models of breast, colon, prostate, lung, glioblastoma, and hematological malignancies, with demonstrated activity against NF-kB, STAT3, EGFR, and survivin signaling. In neuroprotection, honokiol preserves neuronal viability against amyloid-beta toxicity, glutamate excitotoxicity, and oxidative insult through SIRT3-dependent mitochondrial stabilization, reduction of reactive oxygen species, suppression of intracellular calcium elevation, and inhibition of caspase-3 activation. In anxiolysis and sedation, honokiol potentiates GABAergic neurotransmission at concentrations below those required for overt sedation, producing anxiolytic-like behavioral effects in rodent models without the tolerance, dependence, and amnesia liabilities associated with classical benzodiazepines. In inflammation, honokiol suppresses NF-kB-driven proinflammatory cytokine release, reduces glial activation in cerebral ischemia-reperfusion models, and attenuates inflammatory markers in models of sepsis, diabetic nephropathy, and postoperative cognitive decline. The compound readily crosses the blood-brain barrier, a property that distinguishes it from many polyphenols of comparable molecular weight and that supports the observed central nervous system effects. The principal circulating species after oral administration is the monoglucuronide conjugate rather than free honokiol. Clinical evidence in humans is limited. A Phase I trial of liposomal honokiol in patients with relapsed or progressed malignant glioma reported safety, tolerability, and preliminary survival benefit with a dose-response relationship. Phase II trials of liposomal honokiol are ongoing in China. No regulatory authority has approved honokiol as a pharmaceutical agent. The compound is available as a dietary supplement ingredient in several jurisdictions and as a research-grade chemical from multiple suppliers. Investigators should obtain analytical confirmation of identity, purity, and honokiol-to-magnolol ratio on every lot. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.